About Tessera therapeutics
Tessera Therapeutics: Pioneering Gene Writing™ to Cure Diseases at Their Source
Tessera Therapeutics is a biotechnology company that is revolutionizing the field of gene editing with its innovative technology called Gene Writing™. The company's mission is to develop new treatments for genetic diseases by offering the ability to make almost any change to the genome, curing diseases at their source.
Gene Writing™ is a new approach to gene editing that uses synthetic biology and advanced computational tools to design and build custom DNA sequences that can be inserted into cells with high precision. This technology has the potential to cure genetic diseases by correcting or replacing faulty genes, as well as creating entirely new genes that can perform specific functions in cells.
Tessera's team of scientists and engineers are experts in synthetic biology, genomics, bioinformatics, and other related fields. They work together using cutting-edge technologies such as CRISPR-Cas9 gene editing, next-generation sequencing (NGS), and machine learning algorithms to develop novel therapies for a wide range of genetic disorders.
One of Tessera's key strengths is its ability to create custom-designed DNA sequences using its proprietary software platform called Gene Composer™. This platform allows researchers to design DNA sequences from scratch or modify existing ones with high accuracy and efficiency. Once designed, these sequences can be synthesized in the lab using state-of-the-art techniques such as oligonucleotide synthesis or gene assembly methods.
Tessera's Gene Writing™ technology has many potential applications in medicine, including treating rare genetic disorders such as cystic fibrosis or sickle cell anemia. It could also be used for more common conditions like cancer or heart disease by targeting specific genes involved in these diseases.
In addition to developing new therapies based on Gene Writing™ technology, Tessera also collaborates with other companies and academic institutions on research projects related to genetics and genomics. For example, they have partnered with Biogen to develop new treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
Tessera Therapeutics was founded in 2018 by a team of experienced scientists and entrepreneurs with a shared vision of using gene editing to cure genetic diseases. The company is headquartered in Cambridge, Massachusetts, and has received funding from leading venture capital firms such as Flagship Pioneering and GV (formerly Google Ventures).
In conclusion, Tessera Therapeutics is a biotechnology company that is at the forefront of gene editing technology with its innovative Gene Writing™ platform. With its team of experts in synthetic biology, genomics, bioinformatics, and other related fields, Tessera is well-positioned to develop new therapies for a wide range of genetic disorders. By offering the ability to make almost any change to the genome curing diseases at their source, Tessera has the potential to transform medicine as we know it today.